218 Shares in Axon Enterprise, Inc. (NASDAQ:AXON) Acquired by CX Institutional

CX Institutional acquired a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 218 shares of the biotechnology company’s stock, valued at approximately $115,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Axon Enterprise by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock worth $5,019,886,000 after purchasing an additional 275,959 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Axon Enterprise by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock valued at $1,095,542,000 after purchasing an additional 65,097 shares in the last quarter. Capital World Investors boosted its position in Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock worth $1,079,145,000 after purchasing an additional 841,772 shares during the last quarter. Alliancebernstein L.P. boosted its position in Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after purchasing an additional 812,337 shares during the last quarter. Finally, Norges Bank purchased a new position in Axon Enterprise in the fourth quarter worth $482,081,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Trading Down 0.0%

Shares of NASDAQ AXON opened at $780.61 on Tuesday. The business’s 50 day moving average price is $675.00 and its 200-day moving average price is $622.37. The company has a market cap of $60.77 billion, a price-to-earnings ratio of 201.71, a PEG ratio of 5.17 and a beta of 1.29. Axon Enterprise, Inc. has a fifty-two week low of $279.02 and a fifty-two week high of $806.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analysts’ expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 EPS. On average, sell-side analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares of the company’s stock, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joshua Isner sold 9,000 shares of the firm’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $683.31, for a total value of $6,149,790.00. Following the transaction, the president now directly owns 308,714 shares in the company, valued at approximately $210,947,363.34. The trade was a 2.83% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,737 shares of company stock worth $29,797,795. Insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

AXON has been the topic of several research reports. Northcoast Research lowered Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Needham & Company LLC boosted their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. The Goldman Sachs Group lifted their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Craig Hallum lowered Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. Finally, Barclays boosted their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.